Does Tirzepatide or Semaglutide Make You Tired? What the FDA Data Shows

"Does tirzepatide make you tired?" and "does semaglutide make you tired?" are two of the most common real-world questions about these drugs, and neither gets a real answer from the broad GI-focused overviews most sites publish — including our own tirzepatide side effects and semaglutide side effects guides, which focus on nausea, diarrhea and vomiting because that's what dominates the adverse-event tables. Fatigue is a smaller, separate, and genuinely labeled signal in that same FDA data, and it deserves its own answer rather than a footnote.

Fatigue is a labeled adverse reaction, not just anecdote

Both drugs' approvals rested on large randomized placebo-controlled trials — Wegovy's on the STEP program³, Zepbound's on the SURMOUNT program⁴ — and it's the FDA's own pooled adverse-event tables from those trial programs where the numbers below come from. In Zepbound's (tirzepatide) prescribing information, "Fatigue" — a category that explicitly includes asthenia, fatigue, lethargy and malaise — was reported in 3% of placebo-treated patients versus 5% at the 5 mg dose, 6% at 10 mg, and 7% at 15 mg². In Wegovy's (semaglutide) prescribing information, the equivalent combined "Fatigue" category (includes fatigue and asthenia) was reported in 5% of placebo-treated patients versus 11% of patients on the 2.4 mg dose¹ — roughly double the placebo rate, and a noticeably higher absolute rate than tirzepatide's own numbers.

The dose pattern looks different from GI side effects — and that's worth noticing

Zepbound's label is explicit that the dominant GI effects — nausea, vomiting, diarrhea — mostly hit during dose escalation and "decreased over time" once a dose stabilized². No equivalent claim is made about fatigue. Look at the actual numbers again: fatigue rose with dose, from 5% at 5 mg to 6% at 10 mg to 7% at 15 mg² — the opposite of a symptom that's front-loaded during titration and fades. That doesn't mean fatigue never eases for an individual person, but the trial-level pattern doesn't support "it's just an early-weeks thing" the way it does for nausea. Our dosing and titration schedule guide covers what the escalation schedule is actually designed to manage — and, based on this data, fatigue doesn't appear to be one of the things it reliably fixes by week 12.

Real-world reports cluster fatigue with sleep and mood, not just GI symptoms

An observational study of nearly 60,000 Facebook posts mentioning GLP-1 medications grouped commonly co-mentioned adverse events into clusters using network analysis. Fatigue landed in a cluster with insomnia, anxiety, depression and restlessness — separate from the cluster containing nausea, vomiting and pancreatitis, and separate from the cluster containing constipation, dehydration and hypoglycemia⁵. That's social-media pattern-matching, not a mechanism study, and the authors themselves caution it needs rigorous follow-up⁵. But it lines up with something worth taking seriously: for at least some patients, the tiredness they describe may travel more with sleep and mood changes than with stomach upset.

Why would a GLP-1 make you tired? Plausible mechanisms, none proven

No published study has isolated the specific mechanism behind GLP-1-associated fatigue the way the leading telogen-effluvium theory now explains GLP-1 hair loss. What exists instead is a set of physiologically reasonable candidates, none confirmed as *the* cause:

- **Reduced caloric intake itself.** These drugs work specifically by suppressing appetite. Eating meaningfully less — which is the intended effect, not a side effect — is a well-established general contributor to tiredness independent of any drug, and it's plausible that some of what gets reported as drug-caused fatigue is simply what a real calorie deficit feels like. - **GI-effect-driven fluid and electrolyte loss.** Nausea, vomiting and diarrhea are the dominant reactions in both drugs' labels¹²; dehydration from those effects is a mechanistically obvious, if unproven, contributor to feeling drained. - **Slowed gastric emptying and blood sugar changes.** GLP-1s delay gastric emptying and blunt post-meal glucose spikes by design. Both labels flag hypoglycemia risk specifically when combined with insulin or a sulfonylurea, and hypoglycemia is a well-documented cause of fatigue — a mechanism that would apply most to patients also managing type 2 diabetes.

None of these is confirmed by a controlled study designed to isolate it — the same evidence-quality caveat that applies to hair loss applies here. What's real is the adverse-event rate above; what's theoretical is why.

Fatigue is not what makes people quit

Neither label lists fatigue among the leading reasons patients discontinued in the pivotal trials. For Zepbound, the majority of discontinuations due to adverse reactions happened in the first few months and were attributed to gastrointestinal effects specifically². For Wegovy, the most common reasons cited for stopping were nausea (1.8% vs. 0.2% on placebo), vomiting (1.2% vs. 0%) and diarrhea (0.7% vs. 0.1%)¹ — fatigue isn't named in either list. Put together, fatigue is common enough to be labeled and clearly more frequent than placebo, but it doesn't appear to be the thing that actually gets people off the medication the way GI effects do.

What this means before you buy

If you're feeling more tired than usual on tirzepatide or semaglutide, the data says you're not imagining a drug effect — it's in the FDA's own tables at a rate meaningfully above placebo for both molecules. It's also not, on the evidence available, a symptom guaranteed to fade the way nausea typically does, and Zepbound's own numbers trend the other direction with higher doses. Worth raising with your prescriber rather than assuming it away: hydration and electrolytes if GI symptoms are also present, blood sugar if you're on insulin or a sulfonylurea, and general nutritional adequacy, especially protein intake, which also matters for preserving lean mass on a GLP-1 and for energy levels generally during rapid weight loss. If the molecule-vs-molecule tradeoff is still an open question for you, semaglutide vs tirzepatide value covers the efficacy and price side; for the fuller GI-focused safety picture on each drug, see tirzepatide side effects and semaglutide side effects. The trial and FDA sources behind every figure above are collected in our research library. Not medical advice — see our medical disclaimer and talk to a clinician about your own history.